Preview

Научно-практическая ревматология

Расширенный поиск

Психиатрические аспекты спондилоартритов

https://doi.org/10.47360/1995-4484-2020-716-724

Полный текст:

Аннотация

Спондилоартриты относятся к иммуновоспалительным ревматическим заболеваниям, характеризующимся выраженной болью, воспалительной активностью и инвалидизацией пациентов трудоспособного возраста. Одними из наиболее частых коморбидных спондилоартритам заболеваний, утяжеляющих течение и исходы, являются расстройства тревожно-депрессивного спектра. Хроническое воспаление с гиперпродукцией цитокинов оси интерлейкин-23/интерлейкин-17 и нарушением внутриклеточной сигнализации этих цитокинов, развивающееся на фоне нарушения стрессового и иммунного ответа, является ключевым патогенетическим механизмом, объединяющим спондилоартрит и расстройства тревожно-депрессивного спектра и диктующим подходы к их терапии. В статье обсуждаются современные представления о распространенности психических расстройств среди больных спондилоартритом и их негативном влиянии на течение и исходы ревматического заболевания, общности их патогенеза и провоцирующих факторов, влиянии антидепрессантов на исходы спондилоартрита и противовоспалительных препаратов, прежде всего ингибиторов интерлейкина-17 и фактора некроза опухоли альфа, на симптомы расстройств тревожно-депрессивного спектра.

Об авторах

Т. А. Лисицына
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия

Лисицына Татьяна Андреевна

115522, Москва, Каширское шоссе, 34А



Д. Ю. Вельтищев
Московский научно-исследовательский институт психиатрии - филиал ФГБУ Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского Минздрава России; ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России
Россия

107076, Москва, ул. Потешная, 3, корп. 10; 117997, Москва, ул. Островитянова, 1



Е. Л. Насонов
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)
Россия

115522, Москва, Каширское шоссе, 34А; 119991, Москва, ул. Трубецкая, 8, стр. 2



А. М. Лила
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия

125993, Москва, ул. Баррикадная, 2/1, стр. 1; 115522, Москва, Каширское шоссе, 34А



Список литературы

1. Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-660. DOI: 10.14412/1995-4484-2015-657-660

2. Насонов ЕЛ, Галушко ЕА, Гордеев АВ. Современный взгляд на патогенез спондилоартритов — молекулярные механизмы. Научно-практическая ревматология. 2015;53(3):299-307. DOI: 10.14412/1995-4484-2015-299-307

3. Эрдес Ш. Обновленные рекомендации ACR по ведению аксиального спондилоартрита. Научно-практическая ревматология. 2020;58(1):112-116. DOI: 10.14412/1995-4484-2020112-116

4. Walsh JA, Adejoro O, Chastek B, Park Y. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res. 2018;7(4):369-380. DOI: 10.2217/cer-2017-0076

5. Fagerli KM, Kearsley-Fleet L, Watson KD, et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open. 2018;4:e000596. DOI: 10.1136/rmdopen-2017-000596

6. Jacob L, Chevalier T, Kostev K. Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatology International. 2019;39(3):525-531. DOI: 10.1007/s00296-018-4194-y

7. Rodrigues J, Rodrigues AM, Dias SS, Sousa RD, Branco JC, Canhao H. Psoriatic arthritis and ankylosing spondylitis impact on health-related quality of life and working life: A comparative population-based study. Acta Reumatol Port. 2019;44(3):254-265.

8. Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118-126. DOI: 10.1097/BOR.0000000000000152

9. Jang H-D, Park J-S, Kim DW, et al. Relationship between dementia and ankylosing spondylitis: A nationwide, populationbased, retrospective longitudinal cohort study. PLoS ONE. 2019;14(1):e0210335. DOI: 10.1371/journal.pone.0210335

10. Zhao S, Thong Dl, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):140. DOI: 10.1186/s13075-018-1644-6

11. Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020;39(1):217-225. DOI: 10.1007/s10067-019-04734-8

12. Ben Tekaya A, Mahmoud I, Hamdi I, Hechmi S, et al. Depression and anxiety in spondyloarthritis: Prevalence and relationship with clinical parameters and self-reported outcome measures. Turk Psikiyatri Derg. 2019;30(2):90-98. DOI: 10.5080/u20449

13. Jiang Y, Yang M, Lv Q, et al. Prevalence of psychological disorders, sleep disturbance and stressful life events and their relationships with disease parameters in Chinese patients with ankylosing spondylitis. Clin Rheumatol. 2018;37(2):407-414. DOI: 10.1007/s10067-017-3907-z

14. Nie A, Wang C, Song Y, Xie X, Yang H, Chen H. Prevalence and factors associated with disturbed sleep in outpatients with ankylosing spondylitis. Clin Rheumatol. 2018;37(8):2161-2168. DOI: 10.1007/s10067-018-4190-3

15. Chisholm A, Pearce CJ, Chinoy H, Warren RB, Bundy C. Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: A qualitative study. Rheumatology (Oxford). 2016;55(6):1047-1052. DOI: 10.1093/rheumatology/kew009

16. Wu JJ, Penfold RB, Primatesta P, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31(7):1168-1175. DOI: 10.1111/jdv.14175

17. Calandre EP, Rico-Villademoros F, Slim M. Suicidal behaviors in patients with rheumatic diseases: A narrative review. Rheumatol Int. 2018;38(4):537-548. DOI: 10.1007/s00296-017-3909-9

18. Lamb RC, Matcham F, Turner M, et al. Screening for anxiety and depression in people with psoriasis: A cross-sectional study in a tertiary referral setting. J Dermatol. 2017;176(4):1028-1034. DOI: 10.1111/bjd.14833

19. Wang SH, Wang J, Chi CC, et al. Risk for suicidal behavior among psoriasis patients: A nationwide cohort study. Am J Clin Dermatol. 2020;21(3):431-439. DOI: 10.1007/s40257-019-00489-9

20. Shen CC, Hu LY, Yang AC, Kuo BIT, Chiang Y-Y, Tsai S-J. Risk of psychiatric disorders following ankylosing spondylitis: A nationwide population-based retrospective cohort study. J Rheumatol. 2016;43(3):625-631. DOI: 10.3899/jrheum.150388

21. Tu H-P, Yu C-L, Lan C-CE, Yu S. Prevalence of schizophrenia in patients with psoriasis: A nationwide study. J Eur Acad Dermatol Venereol. 2017;31(9):1497-1504. DOI: 10.1111/jdv.14303

22. Gunaydin R, Karatepe AG, Ceyneli N, Kaya T. Fatigue in patients with ankylosing spondylitis: Relationships with disease-specific variables, depression, and sleep disturbance. Clin Rheumatol. 2009;28(9):1045-1051. DOI: 10.1007/s10067-009-1204-1

23. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: Prevalence and associated factors. J Rheumatol. 2014;41(5):887-896. DOI: 10.3899/jrheum.130797

24. Kilic G, Kilic E, Ozgocmen S. Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis. Medicine. 2014;93:e337. DOI: 10.1097/MD.0000000000000337

25. Kotsis K, Voulgari PV, Drosos AA, Carvalho AF, Hyphantis T. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857-872. DOI: 10.1586/14737167.2014.957679

26. Michelsen B, Kristianslund EK, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76(11):1906-1910. DOI: 10.1136/annrheumdis-2017-211284

27. Kossi S, Dadoun S, Geri G, et al. Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: A long-term follow-up of 25 patients. Rheumatology (Oxford). 2017;56(6):896-900. DOI: 10.1093/rheumatology/kew456

28. Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with nonadherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983-1028. DOI: 10.1007/s12325-015-0256-7

29. D’Mello C, Swain MG. Immune-to-brain communication pathways in inflammation-associated sickness and depression. Curr Topics Behav Neurosci. 2017;31:73-94. DOI: 10.1007/7854_2016_37

30. Gaiecki P, Talarowska M. Inflammatory theory of depression. Psychiatr Pol. 2018;52(3):437-447. DOI: 10.12740/PP/76863

31. Himmerich H, Patsalos O, Lichtblau N, Ibrahim MAA, Dalton B. Cytokine research in depression: principles, challenges, and open questions. Front Psychiatry. 2019;10:30. DOI: 10.3389/fpsyt.2019.00030

32. Beurel E, Lowell JA. Th17 cells in depression. Brain, Behavior, and Immunity. 2018;69:28-34. DOI: 10.1016/j.bbi.2017.08.001

33. Debnath M, Berk M. Th17 Pathway-mediated immunopathogenesis of schizophrenia: Mechanisms and implications. Schizophrenia Bulletin. 2014;40(6):1412-1421. DOI: 10.1093/schbul/sbu049

34. Sudo N, Chida Y, Aiba Y, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(1):263-275. DOI: 10.1113/jphysiol.2004.063388

35. Jeffery IB, O’Toole PW, Ohman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997-1006. DOI: 10.1136/gutjnl-2011-301501

36. Liang S, Wang T, Hu X, et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015;310:561-577. DOI: 10.1016/j.neurosci-ence.2015.09.033

37. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med. 2010;10:1. DOI: 10.1186/1472-6882-10-1

38. Pineda ML, Thompson SF, Summers K, de-Leon F, Pope J, Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit. 2011;17(6):CR347-CR354. DOI: 10.12659/msm.881808

39. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-551. DOI: 10.1053/j.gastro.2004.11.050

40. Rao AV, Bested AC, Beaulne TM, et al. A randomized, doubleblind, placebocontrolled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog. 2009;1(6):1-6. DOI: 10.1186/1757-4749-1-6

41. Groeger D, O’Mahony L, Murphy EF, et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325-339. DOI: 10.4161/gmic.25487

42. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, et al. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014;30(4):430-435. DOI: 10.1016/j.nut.2013.09.007

43. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540-543. DOI: 10.1097/01.mcg.0000165671.25272.0f

44. Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized controlled trial. Gastroenterology. 2014;147(6):1327-1337. DOI: 10.1053/j.gastro.2014.08.031

45. D’Mello C, Ronaghan N, Zaheer R, et al. Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain. J Neurosci. 2015;35(30):10821-10830. DOI: 10.1523/JNEUROSCI.0575-15.2015

46. Luo J, Wang T, Liang S, Hu X, Li W, Jin F. Ingestion of Lactobacillus strain reduces anxiety and improves cognitive function in the hyperammonemia rat. Sci China Life Sci. 2014;57(3):327-335. DOI: 10.1007/s11427-014-4615-4

47. Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Infection and work stress are potential triggers of ankylosing spondylitis. Clin Rheumatol. 2006;25(5):660-666. DOI: 10.1007/s10067-005-0131-z

48. Zeboulon-Ktorza N, Boelle PY, Nahal RS, et al. Influence of environmental factors on disease activity in spondyloarthritis: A prospective cohort study. J Rheumatol. 2013;40:469-475. DOI: 10.3899/jrheum.121081

49. Luo G, Boellea PY, Turbelina C, et al. Abrupt and unexpected stressful life events are followed with increased disease activity in spondyloarthritis: A two years web-based cohort study. Joint Bone Spine. 2019;86(2):203-209. DOI: 10.1016/j.jbspin.2018.05.009

50. Anisman H. Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder. J Psychiatry Neurosci. 2009;34(1):4-20.

51. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychol Bull. 2014;140(3):774-815. DOI: 10.1037/a0035302

52. Beutel ME, Brahler E, Wiltink J, et al. New onset of depression in aging women and men: contributions of social, psychological, behavioral, and somatic predictors in the community -CORRIGENDUM. Psychological Medicine. 2019;49(1):175. DOI: 10.1017/S0033291718002787

53. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37(1):137-162. DOI: 10.1038/npp.2011.205

54. Pfau ML, Russo SJ. Peripheral and central mechanisms of stress resilience. Neurobiol Stress. 2015;1:66-79. DOI: 10.1016/j.ynstr.2014.09.004

55. Fagundes CP, Glaser R, Kiecolt-Glaser JK. Stressful early life experiences and immune dysregulation across the lifespan. Brain Behav Immun. 2013;27(1):8-12. DOI: 10.1016/j.bbi.2012.06.014

56. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. Am J Prev Med. 1998;14(4):245-258. DOI: 10.1016/s0749-3797(98)00017-8

57. Andersson NW, Gustafsson LN, Okkels N, et al. Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. Psychol Med. 2015;45(16):3559-3569. DOI: 10.1017/S0033291715001488

58. Marrie RA, Walld R, Bolton JM, et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiology and Psychiatric Sciences. 2019;28(3):333-342. DOI: 10.1017/S2045796017000579

59. Lewinson RT, Vallerand IA, Lowerison MW, et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: A population-based study. J Invest Dermatol. 2017;137(4):828-835. DOI: 10.1016/j.jid.2016.11.032

60. Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: A Cochrane systematic review. J Rheumatol Suppl. 2012;90:21-27. DOI: 10.3899/jrheum.120338

61. Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014;18(5):495-512. DOI: 10.1517/14728222.2014.888417

62. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452-2459. DOI: 10.1038/npp.2011.132

63. Jha MK, Trivedi MH. Personalized antidepressant selection and pathway to novel treatments: Clinical utility of targeting inflammation. Int J Mol Sci. 2018;19(1):E233. DOI: 10.3390/ijms19010233

64. Martino M, Rocchi G, Escelsior A, Fornaro M. Immunomodulation mechanism of antidepressants: Interactions between serotonin/norepinephrine balance and th1/th2 balance. Curr Neuropharmacol. 2012;10(2):97-123. DOI: 10.2174/157015912800604542

65. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: The antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Immunopharmacol. 2006;6(6):903-907. DOI: 10.1016/j.intimp.2005.12.007

66. Ebbinghaus M, Gajda M, Boettger MK, Schaible H-G, Brauer R. The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of th1 and th17 responses. Ann Rheum Dis. 2012;71(2):253-261. DOI: 10.1136/ard.2011.150318

67. Fawcett J, Rush AJ, Vukelich J, Diaz SH, Dunklee L, Romo P, Yarns BC, Escalona R. Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. Am J Psychiatry. 2016;173(2):107-111. DOI: 10.1176/appi.ajp.2015.15060788

68. Lieberknecht V, Junqueira SC, Cunha MP, et al. Pramipexole, a dopamine d2/d3 receptor-preferring agonist, prevents experimental autoimmune encephalomyelitis development in mice. Mol Neurobiol. 2017;54(2):1033-1045. DOI: 10.1007/s12035-016-9717-5

69. Jha MK, Minhajuddin A, Gadad BS, et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the co-med trial. Psychoneuroendocrinology. 2017;78:105-113. DOI: 10.1016/j.psyneuen.2017.01.023

70. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28

71. Jha MK, Minhajuddin A, Gadad BS, Greer TL, Mayes TL, Trivedi MH. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Brain Behav Immun. 2017;66:103-110. DOI: 10.1016/j.bbi.2017.07.005

72. Насонов ЕЛ, Коротаева ТВ, Дубинина ТВ, Лила АМ. Ингибиторы ИЛ23/ИЛ17 при иммуновоспалительных ревматических заболеваниях: новые горизонты. Научно-практическая ревматология. 2019;55(4):400-406. DOI: 10.14412/1995-4484-2019-400-406

73. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:79-85. DOI: 10.1016/j.pnpbp.2013.09.006.

74. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatmentresistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. DOI: 10.1001/2013.jamapsychiatry.4.

75. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, et al. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: The impact on depression, anxiety and quality of life level. Rheumatol Int. 2012;32(2):323-330. DOI: 10.1007/s00296-010-1616-x.

76. Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore). 2016;95(22):e3816. DOI: 10.1097/MD.0000000000003816

77. Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70-80. DOI: 10.1016/j.jaad.2017.08.051.

78. Mikhaylov D, Hashim PW, Nektalova T, Goldenberg G. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: A review of potential risks and benefits. J Clin Aesthet Dermatol. 2019;12(6):46-54 .

79. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273-286. DOI: 10.1111/bjd.14493.

80. Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, et al. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260-267 DOI: 10.1159/000479163

81. Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016; 86(5):260-267. DOI: 10.1159/000479163.

82. Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81-89.e5. DOI: 10.1016/j.jaad.2017.08.024

83. Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, et al. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: Pooled analysis across six clinical trials. Br J Dermatol. 2019;180(1):67-75. DOI: 10.1111/bjd.17149.


Для цитирования:


Лисицына Т.А., Вельтищев Д.Ю., Насонов Е.Л., Лила А.М. Психиатрические аспекты спондилоартритов. Научно-практическая ревматология. 2020;58(6):716-724. https://doi.org/10.47360/1995-4484-2020-716-724

For citation:


Lisitsyna T.A., Veltishchev D.Yu., Nasonov E.L., Lila A.M. Psychiatric aspects of spondyloarthritis. Rheumatology Science and Practice. 2020;58(6):716-724. (In Russ.) https://doi.org/10.47360/1995-4484-2020-716-724

Просмотров: 19


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)